Studying two treatments for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at two treatment approaches for pancreatic cancer. In the first part, a new drug combo called NALIRIFOX is given as the first treatment. In the second part, researchers test whether a special antibiotic can make a common chemo work better by targeting gut bacteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older. If you're over 75, you need to be quite fit (based on a short health questionnaire).
- You should be able to manage daily activities with little to no help (a score of 0 or 1 on a standard scale).
- You must have a confirmed diagnosis of pancreatic cancer that has spread or cannot be removed by surgery.
- You need at least one tumor that can be measured on a CT or MRI scan.
- You must have a stored tissue sample from a previous biopsy or surgery available for research.
- Your blood tests need to show your liver, kidneys, and blood counts are in a certain healthy range.
- If you've never had chemo for advanced cancer, you might qualify for the first part of the study. If you've already had one chemo (like FOLFIRINOX) and it stopped working, you might qualify for the second part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
This trial tests a combination of chemotherapy drugs (NALIRIFOX given through a vein plus paclitaxel given directly into the abdomen) for people with pancreatic cancer that has spread to the lining of the belly but not to other organs. The goal is to see if this approach is safe and effective.
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This study compares two chemotherapy combinations for people with advanced (locally advanced or metastatic) pancreatic cancer that hasn't been treated yet. The goal is to see which combination works better and has fewer side effects.
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
Hear when a new PDAC - Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.